Inhaled therapies targeting prostacyclin pathway in pulmonary hypertension due to COPD: systematic review

Inhaled therapies targeting prostacyclin pathway in pulmonary hypertension due to COPD: systematic review

BackgroundPulmonary hypertension due to chronic obstructive pulmonary disease (COPD) and interstitial lung disease (ILD) is classified as group 3 pulmonary hypertension. Inhaled treprostinil, a prostaglandin I2 analogue also known as prostacyclin, has recently been approved as a first drug for patie...

Full description

Bibliographic Details
Main Authors: Abdullah A. Alqarni, Abdulelah M. Aldhahir, Heba M. Bintalib, Jaber S. Alqahtani, Rayan A. Siraj, Mansour Majrshi, Abdulkareem A. AlGarni, Abdallah Y. Naser, Sara A. Alghamdi, Hassan Alwafi
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-08-01
Series:Frontiers in Medicine
Subjects:
pulmonary hypertension
COPD
prostacyclin
group 3 PH
treprostinil
iloprost
Online Access:https://www.frontiersin.org/articles/10.3389/fmed.2023.1217156/full

Internet

https://www.frontiersin.org/articles/10.3389/fmed.2023.1217156/full

Similar Items